Clinical trials conducted by Li et al. showed that at 24 h and 7 days, serum levels of occludin and MMP-9, markers of BBB damage, were significantly lower in the NBO combined with endovascular treatment (EVT) group compared to the EVT-alone group. Here, MMP9 is linked to chronic recurrent multifocal osteomyelitis.